Only with the ongoing Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) study (NCT03574597) will clinicians understand whether GLP-1 agonists (semaglutide) can reduce MACEs in obese patients with an established CV event (prior myocardial infarction, prior stroke, or peripheral arterial disease) without DM (118). The gene discussed is GLP1R; the disease is Obesity.